ACP prostate Extra Strength

Recommended by Leading Practitioners Worldwide

SCIENCE

Research and Summary Comments
ACP prostate Extra Strength

Saw Palmetto (Serenoa repens)

1. Efficacy and safety of Saw Palmetto Extract Capsules in the treatment of benign prostatic hyperplasia.

We conducted a multi-centered open clinical study on 165 BPH patients treated with Saw Palmetto Extract Capsules at a dose of 160 mg qd for 12 weeks. At the baseline and after 6 and 12 weeks of medication, we compared the International Prostate Symptom Scores (IPSS), prostate volume, postvoid residual urine volume, urinary flow rate, quality of life scores (QOL), and adverse events between the two groups of patients.

Compared with the baseline, both IPSS and QOL were improved after 6 weeks of medication, and at 12 weeks, significant improvement was found in IPSS, QOL, urinary flow rate, and postvoid residual urine. Mild stomachache occurred in 1 case, which necessitated no treatment.
Takeaway:

• Saw Palmetto Extract Capsules are safe and effective for the treatment of BPH.

Nettle (Urtica dioica)

2. Stinging nettle root extract (Bazoton-uno) in long term treatment of benign prostatic syndrome (BPS). Results of a randomized, double-blind, placebo controlled multicenter study after 12 months

Phytotherapy of BPS has a long tradition in Germany; nevertheless, data referring to single phytotherapeutic agents are rare. We therefore performed a randomized, double-blind, placebo-controlled multicenter study for 1 year with Bazoton uno (459 mg dry extract of stinging nettle roots) with 246 patients. The IPSS decreased on average from 18.7+/-0.3 to 13.0+/-0.5 with a statistically significant difference compared to placebo (18.5+/-0.3 to 13.8+/-0.5; p=0.0233). The median Q(max) increased by 3.0+/-0.4 ml/s in comparison to 2.9+/-0.4 ml/s (placebo), thus not statistically significantly different, as well as the median volume of residual urine, which changed from 35.5+/-3.4 ml before therapy to 20.0+/-2.8 ml and from 40.0+/-4.0 ml to 21.0+/-2.9 ml under placebo application.

Treatment with Bazoton uno can therefore be considered a safe therapeutic option for BPS, especially for reducing irritative symptoms and BPS-associated complications due to the postulated antiphlogistic and antiproliferative effects of the stinging nettle extract.
Takeaway:

• Stinging Nettle Root should be viewed as a safe therapeutic option for BPS and its bothersome symptoms.

3. Analysis of the results obtained with a new phytotherapeutic association for LUTS versus control

Two groups of patients who were candidates for surgery for BPH-induced LUTS, were randomly recruited in a six-month trial aimed at comparing outcome of treatment with a new combination of plants extracts (Pluvio®), which differs from the previous ones in that it also contains avocado and soya oil, as well as a high dose of Urtica Dioica, with no therapy. Age, IPSS score, maximal uroflow, prostatevolume, PSA, free-to-total PSA ratio, post voiding residual urine and number of nocturia episodes were recorded and statistically evaluated using a NCSS 60® program.

A marked benefit in terms of quality of life, measured by IPSS score, uroflow, residual urine and nocturia, was observed in the treated group compared to controls. PSA and prostate volume were not significantly affected. No noteworthy adverse events were observed.

The new phytotherapeutic combination evaluated in the present study would seem to be highly effective for the treatment of LUTS (Lower urinary tract symptoms) in BPH patients and does not have negative side effects. Its use could therefore be strongly advocated in this setting.
Takeaway:

• Stinging Nettle Root was highly effective for the treatment of LUTS (Lower urinary tract symptoms) in BPH patients with no side effects.

Diindolylmethane (DIM)

4. Anti-androgenic activity of absorption-enhanced 3, 3′-diindolylmethane in prostatectomy patients.

Consumption of cruciferous vegetables is associated with a decreased risk of developing prostate cancer. Antineoplastic effects of cruciferous vegetables are attributable to bioactive indoles, most prominently, 3, 3′-diindolylmethane (DIM). In addition to effects on proliferation and apoptosis, DIM acts as an antiandrogen in prostate cancer cell lines. This study characterized the effects of prostatic DIM on the androgen receptor (AR) in patients with prostate cancer. Men with localized prostate cancer were treated with a specially formulated DIM capsule designed for enhanced bioavailability (BR-DIM) at a dose of 225 mg orally twice daily for a minimum of 14 days.

After BR-DIM therapy, 96% of patients exhibited exclusion of the AR from the cell nucleus. In contrast, in prostate biopsy samples obtained prior to BR-DIM therapy, no patient exhibited AR nuclear exclusion. Declines in PSA were observed in a majority of patients (71%). Compliance was excellent and toxicity was minimal. In summary, BR-DIM treatment resulted in reliable prostatic DIM levels and anti-androgenic biologic effects at well tolerated doses.
Takeaway:

• These results support further investigation of BR-DIM as a chemopreventive and therapeutic agent in prostate cancer based on the results of this trial.

5. First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN)

Diindolylmethane (DIM) is known as a substance with various anticancer properties. An interim study of the efficacy of a new drug Infemin on the basis of diindolylmethane (DIM) with improved bioavailability has been conducted.

The interim analysis of data included 21 patients diagnosed with a high-grade prostatic intraepithelial neoplasia (PIN). Group 1 (11 patients) received Infemin in a dose of 900 mg of DIM a day, and group 2 (10 patients) received placebo.

To assess the efficacy of therapy, the analysis of morphological index (MI) changes based on the results of histological examinations of prostate biopsy specimens was performed, and a proportion of patients with persistent PIN in 12 months after Infemin initiation was calculated.

After 12 months of treatment in the Infemin group, MI decreased from 0.50 to 0.08, while in the placebo group, it increased from 0.27 to 0.58; the difference between the groups was statistically significant (p = 0.0003, Mann-Whitney test). In 45.5 % of patients in the Infemin group, a complete regression of PIN was also observed, while in the placebo group, PIN regression was not observed in any patients (p = 0.053, Yates’ corrected chi-square).
Takeaway:

The intermediate results of the 21 patients in this study show that DIM-based drug therapy shows promise in patients with high-grade PIN – a precursor to the development of prostate cancer.

Pumpkin seed extract (Cucurbita pepo)

6. Pumpkin Seed Oil Extracted from Cucurbita maxima Improves Urinary Disorder in Human Overactive Bladder.

The pumpkin seed oil obtained from Cucurbita pepo has been shown to be useful for the treatment of nocturia in patients with urinal disorders in several western countries. In this study, we evaluated the effect of the pumpkin seed oil from Cucurbita maxima on urinary dysfunction in human overactive bladder (OAB). Forty-five subjects were enrolled in this study.

An extract of pumpkin seed oil from C. maxima (10 g of oil/day) was orally administrated for 12 weeks. After 6 and 12 weeks, urinary function was evaluated using Overactive Bladder Symptom Score (OABSS). Pumpkin seed oil from C. maxima significantly reduced the degree of OABSS in the subjects.
The results from our study suggest that pumpkin seed oil extracts from C. maxima as well as from C. pepo are effective for urinary disorders such as OAB in humans.
Takeaway:

Study results suggest that pumpkin seed oil extracts from C. maxima as well as from C. pepo are effective for urinary disorders such as OAB.

Lycopene

7. Lycopene inhibits disease progression in patients with benign prostate hyperplasia.

Lycopene is a promising nutritional component for chemoprevention of prostate cancer (PCa). A possibly beneficial role of lycopene in patients diagnosed with benign prostate hyperplasia (BPH), who are at increased risk of developing PCa, has been suggested, although clinical data are lacking. Therefore, this pilot study aimed to investigate the effects of lycopene supplementation in elderly men diagnosed with BPH. A total of 40 patients with histologically proven BPH free of PCa were randomized to receive either lycopene at a dose of 15 mg/d or placebo for 6 mo.

The 6-mo lycopene supplementation decreased PSA levels in men (P < 0.05), whereas there was no change in the placebo group. Whereas progression of prostate enlargement occurred in the placebo group as assessed by trans-rectal ultrasonography (P < 0.05) and digital rectal examination (P < 0.01), the prostate did not enlarge in the lycopene group. Symptoms of the disease, as assessed via the International Prostate Symptom Score questionnaire, were improved in both groups with a significantly greater effect in men taking lycopene supplements. In conclusion, lycopene inhibited progression of BPH. Takeaway:

• Lycopene inhibited progression of BPH in elderly men diagnosed with the disorder.

8. Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer.

Carotenoids are a class of nutrients with antioxidant properties that have been purported to protect against cancer. However, the reported associations between carotenoids and prostate cancer have been heterogeneous and lacking data on interactions with nucleotide sequence variations and genomic biomarkers.
We measured plasma levels of carotenoids and genotyped 20 single nucleotide polymorphisms (SNP) in SOD1, SOD2, SOD3, XRCC1, and OGG1 among 559 men with non-metastatic prostate cancer undergoing radical prostatectomy. We performed copy number analysis in a subset of these men (n = 67) to study tumor instability assessed as Fraction of the Genome Altered (FGA). We examined associations between carotenoids, genotypes, tumor instability and risk of high-grade prostate cancer (Gleason grade ≥ 4 + 3) using logistic and linear regression.

CONCLUSION: Circulating carotenoids at diagnosis, particularly among men carrying specific somatic variations, were inversely associated with risk of high-grade prostate cancer. In exploratory analyses, higher lycopene level was associated with less genomic instability among men with low-grade disease which is novel and supports the hypothesis that lycopene may inhibit progression of prostate cancer early in its natural history.
Takeaway:

• Lycopene may inhibit progression of early-stage prostate cancer.

Zinc

9. The efficacy of zinc for treatment of chronic prostatitis.

Present randomized clinical trial was conducted on 120 patients with diagnosis of chronic prostatitis (IIIA NIH) after preliminary evaluation and ruling out other conditions. The study group received oral zinc sulfate 220 mg daily as capsule without any other supplements. The control group received placebo. Subjects were examined for NIH-CPSI scores every 4 weeks for 12 weeks.

101 subjects completed the study. There were no statistically significant differences in scores and sub-scores of NIH-CPSI between groups before intervention. Decline in the score and sub-scores were more prominent in case group after beginning of the study; though the differences were not statistically significant. Furthermore, the differences in total score and pain score at 12 weeks follow was statistically significant (p=0.003 and p=0.02, respectively).
Takeaway:

• Zinc supplements may benefit in management of patients with chronic prostatitis – related to antibacterial and immunomodulatory functions of zinc.

Pygeum (Pygeum africanum)

10. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe.

Pygeum africanum extract is available as Tadenan in many countries, including those in central and eastern Europe, for the treatment of mild to moderate BPH. Its efficacy and acceptability have been demonstrated in numerous open and placebo-controlled studies in large populations.

The present open three-centre efficacy and safety study was conducted according to common protocol at urology clinics in the Czech and Slovak Republics and in Poland, in order to confirm the therapeutic profile of Pygeum africanum in conditions of daily practice, using International Prostate Symptom Score (IPSS) and flowmetry assessments. Men aged 50-75 years and in compliance with the selection criteria (including IPSS > or = 12, quality of life (QoL) score > or = 3, and maximum urinary flow < or = 15 ml/s) were first examined then recalled after two weeks during which no treatment was provided (washout and check of stability). If still compliant, they were entered at this point into a two-month period of treatment with Pygeum africanum extract 50 mg twice daily. There followed a further one-month period without treatment, the objective being to evaluate the persistence of any effects observed during the previous two months of Pygeum africanum administration. The primary efficacy parameter investigated was IPSS; the other efficacy parameters were QoL, nocturnal frequency, maximum urinary flow, average urinary flow, post-voiding residual volume and prostatic volume, after one and two months of Pygeum africanum treatment and one month after stopping treatment. A total of 85 patients were evenly distributed between the three centres and completed the entire study. At inclusion their mean IPSS was 16.17, QoL was 3.60 and nocturia was 2.6 times per night. The changes in subjective scores, IPSS and QoL after the two-month treatment period were highly statistically significant with mean improvements of 40% and 31%, respectively. Nocturnal frequency was reduced by 32% and the mean reduction was again highly statistically significant. Mean maximum urinary flow, average urinary flow and urine volume were also statistically significantly improved, but the modest improvement in post-voiding volume did not reach statistical significance. The improvements, which exceeded those observed with placebo in earlier studies, were maintained after one month without treatment indicating an interesting persistence of clinically useful activity. Takeaway:

• Pygeum africanum is viable option for BPH, urinary flow and overall impact on related quality of life issues associated with prostate disorders.

Beta-sitosterol

11. Blockade of Androgen Markers Using a Novel Betasitosterol, Thioctic Acid and Carnitine-containing Compound in Prostate and Hair Follicle Cell-based Assays.

Androgenetic alopecia (AGA) affects approximately 70% of men and 40% of women in an age-dependent manner and is partially mediated by androgen hormones. Benign prostatic hyperplasia (BPH) similarly affects 50% of the male population, rising by 10% each decade. Finasteride inhibits 5-alpha reductase (5AR) and is used to treat both disorders, despite offering limited clinical benefits accompanied by significant adverse side effects. Building on our previous work demonstrating the efficacy of naturally derived 5AR inhibitors (such as stigmasterol and beta sitosterol), we hypothesize that targeting 5AR as well as inflammatory pathways may yield improved efficacy in AGA and BPH. Here we address these dual pathomechanisms by examining the potency of a novel composition using in vitro assays of representative cell lines for AGA (hair follicle dermal papilla cells) and BPH (LNCaP prostate cells), respectively.

Exposure of cells to the novel test composition down-regulated mRNA expression profiles characteristic of both disease processes, which outperformed finasteride. Changes in mRNA expression were corroborated at the protein level as assessed by western blotting.
Takeaway:

• beta sitosterol outperformed finasteride in this trial and may represent a rational approach to treating AGA and BPH by simultaneously targeting 5AR and inflammatory mediators.

Tribulus (Tribulus terrestris)

12. Clinical study of Tribulus terrestris Linn. in Oligozoospermia: A double blind study.

Infertility is a problem of global proportions, affecting on an average 8-12% of couples worldwide. Low sperm count (Oligozoospermia) is one of the main causes of male infertility and it is correlated with Kshina Shukra. The fruits of Gokshura (Tribulus terrestris. Linn) are considered to act as a diuretic and aphrodisiac; they used for urolithiasis, sexual dysfunctions, and infertility.

Hence, it was planned to study the effect of Gokshura in the management of Kshina Shukra (Oligozoospermia), and to evade the preconception, a double-blind, randomized, placebo-controlled study was designed. In this study, eligible subjects between the age of 21 and 50 years, with a complaint of Kshina Shukra (Oligozoospermia), were randomized to receive either Gokshura granules or placebo granules for 60 days.

The primary outcome measures were percentage changes in the Pratyatmaka Lakshanas (cardinal symptoms) of Kshina Shukra, Agni bala, Deha bala, Satva bala, the semenogram, and in the Quality of the Sexual Health Questionnaire. The placebo granules showed 70.95% improvement, whereas, the Gokshura granules showed 78.11% improvement in Rogi bala (Agni bala, Deha bala, Satva bala, and the Quality of Sexual Health) and Rogabala (Semen Analysis and Pratyatmaka Lakshanas).

The Gokshura granules have shown superior results in the management of Kshina Shukra, as compared to the placebo granules.
Takeaway:

• Tribulus terrestris, in this trial, showed superior results in the management of Kshina Shukra (Oligozoospermia – low sperm count).

Citation links:
1. https://www.ncbi.nlm.nih.gov/pubmed/21969849
2. https://www.ncbi.nlm.nih.gov/pubmed/15045190
3. https://www.ncbi.nlm.nih.gov/pubmed/16708583
4. https://www.ncbi.nlm.nih.gov/pubmed/27069550
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818865/
6. https://www.ncbi.nlm.nih.gov/pubmed/24872936
7. https://www.ncbi.nlm.nih.gov/pubmed/18156403
8. https://www.ncbi.nlm.nih.gov/pubmed/26585352
9. https://www.ncbi.nlm.nih.gov/pubmed/24448329
10. https://www.ncbi.nlm.nih.gov/pubmed/9787978
11. https://www.ncbi.nlm.nih.gov/pubmed/26990224
12. https://www.ncbi.nlm.nih.gov/pubmed/23723641

DOSAGE GUIDELINES

Standard Dose

Take 6 sprays by mouth, twice daily.

Higher Dose

Take 12 sprays by mouth, twice daily.

Optimal Use

  • Spray, swish and swallow. You may take other Results RNA formulas immediately.
  • Do not eat or drink for 2 minutes following.
  • Take as recommended by your physician.
SUPPLEMENT FACTS

SERVING SIZE

Serving size: 12 Sprays

Servings Per Container (2oz/60mL): Approx. 30
Servings Per Container (4oz/120mL): Approx. 60

AMOUNT PER SERVING
Proprietary Blend Tincture 250 mg*

INGREDIENTS

Ingredients

Saw Palmetto (Serenoa repens), Nettle (Urtica dioica), Diindolylmethane (DIM), Pumpkin seed extract (Cucurbita pepo), Lycopene, Zinc, Pygeum (Pygeum africanum), Beta-sitosterol, Tribulus (Tribulus terrestris), Peppermint Leaf (Mentha x piperita) and Natural Trace Minerals.

Other Ingredients: Ultra-Pure Deionized Water

* % Daily value not established

BEST RESULTS

For Best Results:

Take Prostate Care with ACS 200 and ACZ Nano Extra Strength to achieve optimal prostate health and total body detoxification.

The Leading Prostate Health Formula
ACP Prostate Extra Strength is the most advanced prostate health supplement available. With simple-to-take intra-oral spray delivery, ACP prostate delivers greater quantities of active nutrients to targeted living cells than could ever be possible with capsules or pills.

Clinically Proven
The active ingredients in ACP Prostate have been shown to help maintain healthy prostate size and PSA levels in numerous clinical studies, and include: Saw Palmetto (Serenoa repens), Nettle (Urtica dioica), Diindolylmethane (DIM), Pumpkin seed extract (Cucurbita pepo), Lycopene, Zinc, Pygeum (Pygeum africanum), Beta-sitosterol, Tribulus (Tribulus terrestris), Peppermint Leaf (Mentha x piperita) and Natural Trace Minerals.

Fast Acting and Safe
Significant benefit can be felt within the first month of product use. Daily use provides increased and continual benefit.

2 oz $29.95
4 oz $49.95

Healthy Prostate. Healthy Libido
Case Studies have shown ACP Prostate Extra Strength to be effective in reducing Prostate Specific Antigen (PSA) levels and maintaining healthy prostate size. Patients using ACP Prostate have also reported healthier and stronger libido.

Improve Urinary Flow. Reduce Urgency
Ingredients in ACP Prostate have been shown to support a reduction in BPH (Benign prostatic hyperplasia) symptoms translating to Improved urinary flow and reduced frequency of nighttime bathroom visits.

Advanced Cellular Technology
Delivers the power of each ingredient in the most effective manner possible; achieving maximum results without stomach discomfort or side effects.* No capsules or pills, Results RNA Extra Strength Intra-oral sprays are immediately absorbed, simple to take, and have a pleasant taste. Just spray, swish, and swallow.

Prostate Facts:

  • The prostate is a variable-sized gland located in the male pelvis and is part of a man’s reproductive system. The prostate’s main function is to produce fluid for semen, which aids in the transport of sperm. The prostate is about the size and shape of a walnut and is located below the bladder.
  • Prostate cancer is the most common cancer for males over 40 and is expected to kill over 30,000 men this year alone, according to the American Cancer Society.

Purity and Quality Guaranteed:

gmp_logoACP prostate Extra Strength is produced under strict GMP manufacturing controls in conformance with guidelines for dietary supplements set forth in USP XXVII. For purity and quality, ACP prostate contains no preservatives • no alcohol • no artificial coloring or flavoring. For customer support, please call 1 888 823 3869.